AB
The startup has developed a single-use, end-to-end autologous cell manufacturing platform that enables bedside production of life-saving therapies. This system enhances quality assurance, reduces time to market, and lowers costs, ensuring greater availability of advanced cell therapies for patients.
Updated 3 months ago
Funding
$620K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup has developed a single-use, end-to-end autologous cell manufacturing platform that enables bedside production of life-saving therapies. This system enhances quality assurance, reduces time to market, and lowers costs, ensuring greater availability of advanced cell therapies for patients.